
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics

